DK1512014T3 - Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation - Google Patents

Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation

Info

Publication number
DK1512014T3
DK1512014T3 DK03738030T DK03738030T DK1512014T3 DK 1512014 T3 DK1512014 T3 DK 1512014T3 DK 03738030 T DK03738030 T DK 03738030T DK 03738030 T DK03738030 T DK 03738030T DK 1512014 T3 DK1512014 T3 DK 1512014T3
Authority
DK
Denmark
Prior art keywords
transplantation
allo
antigens
alloantigens
identifying
Prior art date
Application number
DK03738030T
Other languages
Danish (da)
English (en)
Inventor
Wolfgang Strittmatter
Heidrun Moll
Burkhard Scharm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK1512014T3 publication Critical patent/DK1512014T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46434—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
DK03738030T 2002-06-13 2003-06-13 Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation DK1512014T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013423 2002-06-13
PCT/EP2003/006251 WO2003106692A2 (en) 2002-06-13 2003-06-13 Methods for the identification of all-antigens and their use for cancer therapy and transplantation

Publications (1)

Publication Number Publication Date
DK1512014T3 true DK1512014T3 (da) 2009-10-05

Family

ID=29724392

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03738030T DK1512014T3 (da) 2002-06-13 2003-06-13 Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation

Country Status (11)

Country Link
US (1) US20050244421A1 (de)
EP (2) EP2110669B1 (de)
JP (2) JP2005529187A (de)
AT (2) ATE519115T1 (de)
AU (1) AU2003245942B2 (de)
CA (1) CA2489296A1 (de)
DE (1) DE60328685D1 (de)
DK (1) DK1512014T3 (de)
ES (2) ES2370688T3 (de)
PT (1) PT1512014E (de)
WO (1) WO2003106692A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370688T3 (es) * 2002-06-13 2011-12-21 Merck Patent Gmbh Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante.
JP2005102599A (ja) * 2003-09-30 2005-04-21 Shimadzu Corp Ｈｌａタイピング法
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
PL1866328T3 (pl) * 2005-03-22 2011-05-31 Rohto Pharma Peptydy zwiększające wytwarzanie kolagenu lub kwasu hialuronowego
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
WO2007101227A2 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3103463B1 (de) 2007-09-19 2020-01-01 Pluristem Ltd. Adhärente zellen aus fett- oder plazentagewebe und verwendung davon in der therapie
US20120165211A1 (en) * 2007-09-20 2012-06-28 Bracco Imaging S.P.A. Human Antibodies Cross-Reacting With A Bacterial And A Self Antigen From Atherosclerotic Plaques
US20100316563A1 (en) * 2007-09-20 2010-12-16 Bracco Imaging S.P.A. Method For The Preparation Of New Oligoclonal Antibodies
WO2009146213A2 (en) 2008-04-18 2009-12-03 The University Of Tennessee Research Foundation Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
AU2009252722A1 (en) * 2008-05-27 2009-12-03 Pluristem Ltd. Methods of treating inflammatory colon diseases
WO2010026735A1 (ja) * 2008-09-05 2010-03-11 国立大学法人名古屋大学 アミロイドβ凝集促進ペプチド及びその用途
ES2788863T3 (es) * 2010-05-14 2020-10-23 Massachusetts Gen Hospital Composiciones de neoantígenos específicos de un tumor para uso en el tratamiento de tumores
WO2011163258A2 (en) * 2010-06-21 2011-12-29 Pharmason Labs, Inc. Compositions and methods for diagnosing and monitoring disease and treatment via antigen-specific molecules
BR112013029834A8 (pt) 2011-05-24 2022-10-18 Biontech Ag vacinas individualizadas para câncer
RU2508552C2 (ru) * 2011-06-17 2014-02-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Минздравсоцразвития России" Способ прогнозирования развития злокачественных солидных опухолей у детей и подростков
KR101912982B1 (ko) * 2012-03-06 2018-10-29 셀렉트 바이오테라퓨틱스 리미티드 세포자멸사-신호전달 내성 세포를 선택하기 위한 디바이스 및 방법, 그리고 그의 용도
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10155031B2 (en) 2012-11-28 2018-12-18 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3083684A1 (de) 2013-12-06 2016-10-26 NovImmune SA Antikörper gegen tlr4 und verfahren zur verwendung davon
CN106456724A (zh) 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
JP7044551B2 (ja) 2014-09-10 2022-03-30 ジェネンテック， インコーポレイテッド 免疫原性変異体ペプチドスクリーニングプラットフォーム
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
TWI806815B (zh) 2015-05-20 2023-07-01 美商博德研究所有限公司 共有之ｇａｔａ３相關之腫瘤特異性新抗原
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
AU2017331362A1 (en) * 2016-09-23 2019-03-14 Fred Hutchinson Cancer Center TCRs specific for minor histocompatibility (H) antigen HA-1 and uses thereof
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
CA3065325A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
EP4038222A4 (de) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Verfahren und zusammensetzungen zur identifizierung von neoantigenen zur verwendung bei der behandlung und vorbeugung von krebs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837477A (en) * 1993-01-15 1998-11-17 The United States Of America As Represented By The Department Of Health And Human Services T cell receptor ligands and methods of using same
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5770201A (en) 1994-12-23 1998-06-23 Rijsuniversiteit Te Leiden HA-2 antigenic peptide
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
EP0840750B1 (de) * 1995-07-25 2006-03-01 Rijksuniversiteit te Leiden Antigenische ha-2 peptide
JPH11511129A (ja) 1995-07-27 1999-09-28 リュークスウニベルジテート トゥ ライデン Ｈ−ｙ抗原
DE69833120T2 (de) 1997-07-23 2007-03-01 Rijksuniversiteit Leiden Verfahren zur Typisierung des HA-1 Nebenhistokompatibilitätsantigens
EP1020519A1 (de) * 1999-01-15 2000-07-19 Introgene B.V. Nebenhistokompatibilitätsantigene, und deren Verwendung zur Diagnose und Behandlung von Tumoren
EP1067141A1 (de) 1999-06-11 2001-01-10 Rijksuniversiteit te Leiden Ein für Männer spezifisches Proteinhomologes, das im Zusammenhang mit der Histokompatibilität steht
WO2001078708A1 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Treating graft rejection with cxcr3 inhibitors
US20030148321A1 (en) * 2001-08-24 2003-08-07 Iris Pecker Methods and kits for diagnosing and monitoring hematopoietic cancers
ES2370688T3 (es) * 2002-06-13 2011-12-21 Merck Patent Gmbh Métodos para la identificación de alo-antígenos y su utilización para la terapia contra el cáncer y para el trasplante.

Also Published As

Publication number Publication date
DE60328685D1 (de) 2009-09-17
EP2110669A1 (de) 2009-10-21
PT1512014E (pt) 2009-11-10
ES2329461T3 (es) 2009-11-26
WO2003106692A2 (en) 2003-12-24
EP1512014B1 (de) 2009-08-05
US20050244421A1 (en) 2005-11-03
JP2010252806A (ja) 2010-11-11
EP1512014A2 (de) 2005-03-09
ATE438857T1 (de) 2009-08-15
ES2370688T3 (es) 2011-12-21
AU2003245942B2 (en) 2008-07-24
AU2003245942A1 (en) 2003-12-31
JP2005529187A (ja) 2005-09-29
EP2110669B1 (de) 2011-08-03
ATE519115T1 (de) 2011-08-15
WO2003106692A3 (en) 2004-12-23
CA2489296A1 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
DK1512014T3 (da) Fremgangsmåder til identifikation af alloantigener samt anvendelse deraf til cancerbehandling og transplantation
ES2836273T3 (es) Método para el tratamiento del cáncer
EA202091335A1 (ru) Ограниченные hla класса i t-клеточные рецепторы против мутантного ras
EA200971124A1 (ru) Множественный анализ образцов крови
DK1187591T3 (da) IBD-associerede mikrobielle antigener og fremgangsmåder til at anvende samme
EP1565489A4 (de) Neues raag10-zelloberflächenziel und dieses ziel erkennende antikörperfamilie
EA202090757A1 (ru) T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53
ATE506962T1 (de) Von survivin abgeleitete peptide und deren verwendung
ATE391723T1 (de) Verfahren zur identifizierung antigener peptide
MX2021015033A (es) Clasificacion con contraseleccion utilizando peptidos de secuencias similares.
NO20054351L (no) Monoklonalt antistoff og hybridom som produserer dette
CA2735138C (en) Screening methods for transfusion related acute lung injury (trali)
WO2020014097A8 (en) Reagents and methods for treating cancer and autoimmune disease
ES2421558T3 (es) Anticuerpos específicos de cáncer y proteínas de superficie celular
PH12021550470A1 (en) Improved anti-flt3 antigen binding proteins
WO2020117778A3 (en) Reagents and methods for controlling protein function and interaction
MX2021014952A (es) Molecula de union especifica para cd73 y uso de la molecula de union.
ATE316577T1 (de) Das goodpasture-antigen bindende protein
EA202091713A1 (ru) Биологический синтез аминокислотных цепей для получения пептидов и белков
MX2021000853A (es) Vacunas individualizadas para el cancer.
ZA200500214B (en) Method for mapping and eliminating T-cell epitopes.
ZA202103675B (en) Method for analyzing a blood sample from a human for a tuberculosis disease by detection of tb antigen-stimulated cd154 expression in combination with cd38, ki-67 or hla-dr
HUP0400661A2 (hu) Specifikus tumorantigének azonosítása cDNS-könyvtárak szérumokkal történő szelekciójával, és az antigének alkalmazása daganatok kezelésében
ATE496129T1 (de) Von hla-klasse-ii-molekülen präsentierte ssx-2- peptide
WO2006089002A3 (en) Method for high throughput screening for antibodies and proteins inducing apoptosis